New Cervical Cancer Vaccine In The Works

A second cervical cancer vaccine may soon be available.

Drug-maker Glaxo-Smith-Kline is asking the food and drug administration to approve its cervical cancer vaccine called "Cervarix." The company just submitted final data on a phase iii clinical study involving more than 18,000 teen girls and women.

Like Merck's Gardasil already on the market, Cervarix works by protecting against the human papillomavirus, which is a cause of cervical cancer.

Cervarix is currently used in more than 90 countries. It could be approved by the FDA within about 6 months.

Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus

275 E. Arlington Blvd. Greenville, NC 27858 252-439-7777
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 42181437 -
Gray Television, Inc.